Skip to main content
B

Bora Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 6472 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 21 across all filing types
Latest filing 2026-03-30 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 6472

About Bora Pharmaceuticals Co., Ltd.

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
114年度營益分析
Interim / Quarterly Report Classification · 1% confidence The document is a structured financial data table provided by a listed company (保瑞) via the Market Observation Post System (公開資訊觀測站). It contains comprehensive quarterly and annual financial performance metrics (revenue, gross margin, operating margin, etc.) for multiple fiscal years. Since it provides substantive financial data and analysis for specific periods rather than just an announcement of a report, it is classified as an Interim/Quarterly Report (IR). 9M 2025
2026-03-30 Chinese
114年第4季權益變動表
Interim / Quarterly Report Classification · 1% confidence The document is a 'Consolidated Statement of Changes in Equity' (合併權益變動表) provided by a company (保瑞) for the fiscal year 2025. It contains detailed financial data, including opening and closing balances, net income, dividends, and equity adjustments. As it provides substantive financial statements for a specific period, it falls under the category of an Interim or Quarterly Report (IR), as it is a component of the comprehensive financial reporting package. FY 2025
2026-03-30 English
114年第4季現金流量表
Interim / Quarterly Report Classification · 1% confidence The document is a Consolidated Statement of Cash Flows for 'Baorui' (保瑞公司) for the 4th quarter of the 114th year (Republic of China calendar). It provides detailed financial data, including operating, investing, and financing cash flow line items. Since it contains substantive financial statements for a specific period (quarterly) and is not merely an announcement or certification, it is classified as an Interim/Quarterly Report. Q4 2025
2026-03-30 Chinese
114年第4季綜合損益表
Interim / Quarterly Report Classification · 1% confidence The document is a consolidated statement of comprehensive income (合併綜合損益表) provided by a company (保瑞) for the 4th quarter of the 114th year (Republic of China calendar). It contains detailed financial data, including revenue, operating costs, expenses, and earnings per share. Since it provides substantive financial statements for a specific period (quarterly), it is classified as an Interim/Quarterly Report (IR). Q4 2025
2026-03-30 Chinese
114年第4季資產負債表
Interim / Quarterly Report Classification · 1% confidence The document is a consolidated balance sheet for '保瑞公司' (Bora Pharmaceuticals) for the 4th quarter of the 114th year (Republic of China calendar). It provides detailed financial data including assets, liabilities, and equity, which is characteristic of a quarterly financial report. Since it contains substantive financial statements rather than just an announcement or certification, it is classified as an Interim/Quarterly Report. Q4 2025
2026-03-30 Chinese
公告本公司國內第四次無擔保轉換公司債收足應募價款
Capital/Financing Update Classification · 1% confidence The document is an announcement by the company that its domestic fourth unsecured convertible bonds have received full subscription proceeds of NT$2,020,000,000. This is a financing activity update regarding the issuance of convertible debt and the collection of funds. It does not present financial results, AGM materials, or regulatory form attachments. It clearly fits the Capital/Financing Update category.
2026-03-30 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.